Systemic Hyperthermia Combined with Chemotherapy: A Pilot Clinical Trial in the Treatment of Metastatic Gastrointestinal Cancers DOI Open Access

Mohammad Ali Broomand,

Maryam Kalantari Khandani,

Saleh Sandoughdaran

et al.

International Journal of Cancer Management, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 22, 2025

Background: Hyperthermia, which involves heating body tissues to enhance cancer treatment efficacy, has been explored as an adjunctive therapy improve chemotherapy outcomes. Whole-body hyperthermia (WBH) offers a potential synergistic approach by sensitizing cells chemotherapeutic agents and enhancing drug delivery. Objectives: This study aimed evaluate the efficacy safety of combining systemic with WBH in patients metastatic gastrointestinal cancers. Methods: A pilot was conducted at Shohada Tajrish Hospital. Patients pathologically confirmed cancers were treated standard combined WBH. Hyperthermia applied using infrared devices, maintaining temperatures between 39°C 40.5°C. kept this plateau for 1.5 hours, receiving concurrently. Chemotherapy drugs administered 80% dose. After completion WBH, observed hospital 24 hours ensure safety. Data on patient demographics, tumor characteristics, regimens, adverse events systematically collected analyzed. Results: total 20 (mean age: 54.8 years) participated study, equal distribution male female participants. The mean number cycles 4.6 4.9, respectively. Clinical response rates included 5% (1 patient) complete (CR), 40% (8 patients) partial (PR), 35% (7 stable disease (SD). overall control rate (DCR) — comprising CR, PR, SD 80%, all responses who had received least six hyperthermia. Most experienced either no or only grade 1 toxicities. most frequently effects diarrhea (45%) vomiting (43%), indicating that symptoms common. Severe toxicities (grade 4) rare, occurring approximately 2% cases. Conclusions: is viable well-tolerated therapeutic strategy cancers, demonstrating favorable toxicity profile promising rates. Additional large-scale studies are suggested confirm these findings investigate mechanisms underlying improved efficacy.

Language: Английский

Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies DOI Creative Commons
Fan Xu, Yao Liu, Zujun Que

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

Metastasis is the leading cause of death in patients with lung cancer. Multidisciplinary comprehensive treatments (MDT), including surgery, chemotherapy, radiotherapy, gene-targeted therapy, immunotherapy, antibody-drug conjugate (ADC), natural products, etc., have been currently used for cancer metastasis. The MDT model has shown promising efficacy against metastasis clinical practice. However, these therapies some limitations, such as unusual toxic side effects, drug resistance, limited indications, and high costs. Therefore, emerging technological platforms are imperative to overcome bottlenecks. Nanomedicine can be prepare efficient delivery systems owing its good biocompatibility, targeting, responsive release, multidrug codelivery plays an important role synergistic antimetastasis because optical, acoustic, electrical, thermal, magnetic functions. This review analyses limitations model, briefly outlines advantages nanotechnology, introduces nanodrug systems, summarizes nanostrategies based on invasion-metastasis cascade process, provides a summary prospects challenges translation nanomedicines.

Language: Английский

Citations

0
Surfactant-based drug delivery systems for cancer therapy: Advances, challenges, and future perspectives DOI

Karuppiah Nagaraj

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125655 - 125655

Published: May 1, 2025

Language: Английский

Citations

0
Systemic Hyperthermia Combined with Chemotherapy: A Pilot Clinical Trial in the Treatment of Metastatic Gastrointestinal Cancers DOI Open Access

Mohammad Ali Broomand,

Maryam Kalantari Khandani,

Saleh Sandoughdaran

et al.

International Journal of Cancer Management, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 22, 2025

Background: Hyperthermia, which involves heating body tissues to enhance cancer treatment efficacy, has been explored as an adjunctive therapy improve chemotherapy outcomes. Whole-body hyperthermia (WBH) offers a potential synergistic approach by sensitizing cells chemotherapeutic agents and enhancing drug delivery. Objectives: This study aimed evaluate the efficacy safety of combining systemic with WBH in patients metastatic gastrointestinal cancers. Methods: A pilot was conducted at Shohada Tajrish Hospital. Patients pathologically confirmed cancers were treated standard combined WBH. Hyperthermia applied using infrared devices, maintaining temperatures between 39°C 40.5°C. kept this plateau for 1.5 hours, receiving concurrently. Chemotherapy drugs administered 80% dose. After completion WBH, observed hospital 24 hours ensure safety. Data on patient demographics, tumor characteristics, regimens, adverse events systematically collected analyzed. Results: total 20 (mean age: 54.8 years) participated study, equal distribution male female participants. The mean number cycles 4.6 4.9, respectively. Clinical response rates included 5% (1 patient) complete (CR), 40% (8 patients) partial (PR), 35% (7 stable disease (SD). overall control rate (DCR) — comprising CR, PR, SD 80%, all responses who had received least six hyperthermia. Most experienced either no or only grade 1 toxicities. most frequently effects diarrhea (45%) vomiting (43%), indicating that symptoms common. Severe toxicities (grade 4) rare, occurring approximately 2% cases. Conclusions: is viable well-tolerated therapeutic strategy cancers, demonstrating favorable toxicity profile promising rates. Additional large-scale studies are suggested confirm these findings investigate mechanisms underlying improved efficacy.

Language: Английский

Citations

0